Evelo Biosciences (EVLO) Competitors $0.0005 0.00 (0.00%) As of 09:31 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EVLO vs. SYRS, NEXI, VRPX, SCPS, VAXX, ARDS, NAVB, CMRA, GNCAQ, and GNCAShould you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Syros Pharmaceuticals (SYRS), NexImmune (NEXI), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Evelo Biosciences vs. Its Competitors Syros Pharmaceuticals NexImmune Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Aridis Pharmaceuticals Navidea Biopharmaceuticals Comera Life Sciences Genocea Biosciences Genocea Biosciences Syros Pharmaceuticals (NASDAQ:SYRS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Which has more volatility & risk, SYRS or EVLO? Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Is SYRS or EVLO more profitable? Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Evelo Biosciences N/A N/A N/A Which has better valuation and earnings, SYRS or EVLO? Evelo Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.01-$164.57M-$3.030.00Evelo BiosciencesN/AN/A-$114.53MN/AN/A Do analysts recommend SYRS or EVLO? Syros Pharmaceuticals presently has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Evelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Evelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in SYRS or EVLO? 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer SYRS or EVLO? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral Evelo Biosciences Neutral SummarySyros Pharmaceuticals beats Evelo Biosciences on 6 of the 9 factors compared between the two stocks. Get Evelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVLO vs. The Competition Export to ExcelMetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9K$932.07M$5.70B$10.42BDividend YieldN/A4.84%5.78%4.69%P/E RatioN/A1.2375.6626.39Price / SalesN/A26.47540.28125.20Price / CashN/A17.6425.6730.68Price / BookN/A6.6112.826.40Net Income-$114.53M-$5.42M$3.29B$276.69M7 Day PerformanceN/A4.73%1.12%-0.28%1 Month PerformanceN/A3.33%4.53%6.69%1 Year PerformanceN/A27.27%67.99%27.62% Evelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120SYRSSyros Pharmaceuticals3.2987 of 5 stars$0.00-45.5%$1.00+166,566.7%-100.0%$16K$386K0.00120Gap DownNEXINexImmuneN/A$0.01flatN/A-99.9%$14KN/A0.006VRPXVirpax Pharmaceuticals0.1514 of 5 stars$0.01+9.9%N/A-99.9%$14KN/A0.007Gap UpSCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009VAXXVaxxinityN/A$0.00-90.0%N/A-50.0%$13KN/A0.0090ARDSAridis PharmaceuticalsN/A$0.00-84.6%N/AN/A$11KN/A0.0030Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$10K$8.13K0.0010Gap DownHigh Trading VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies SYRS Alternatives NEXI Alternatives VRPX Alternatives SCPS Alternatives VAXX Alternatives ARDS Alternatives NAVB Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVLO) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
